| Abstrakt: |
A recent review conducted by the Woolcock Institute of Medicine Research in Sydney, Australia, explores the use of two pressurized metered dose inhalers, Fostair and Trimbow, for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Fostair combines an inhaled corticosteroid and a long-acting beta2-agonist, while Trimbow integrates a tri-particulate formulation consisting of an inhaled corticosteroid, a long-acting beta2-agonist, and glycopyrronium bromide. Clinical trials have shown that Trimbow may be more effective than Fostair in reducing exacerbation rates and improving lung function. However, further research is needed to optimize therapeutic outcomes and address existing knowledge gaps. [Extracted from the article] |
